EUVIMEDEUVIMED entdecken
Open Access

Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

Nancy W Wei iD, Sunny Chi, Mark G Lebwohl

Journal of Psoriasis and Psoriatic Arthritis · 2022-04 · 7 (2) · 55-59

DOI: 10.1177/24755303221077211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Psoriasis and Psoriatic Arthritis, online erschienen am 29.03.2022. Verfasst von Nancy W Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin (IL)-23 antagonists have shown great efficacy with minimal side effect profile in clinical trial data for the treatment of moderate to severe plaque psoriasis. As of yet, there have been no published data regarding real-world patients who have received tildrakizumab therapy.

Objectives

To analyze real-world efficacy and safety of tildrakizumab in patients with moderate to severe plaque psoriasis.

Methods

A retrospective chart review was performed at a large urban academic medical center for all patients treated with tildrakizumab for moderate to severe plaque psoriasis. Demographic information, Psoriasis Area and Severity Indexs(PASIs) from initial presentation and 12-month follow-up, comorbidities, and any possible adverse events were collected and analyzed statistically.

Results

30 patients on tildrakizumab therapy were included in the analysis. Overall, the mean ± standard deviation of the PASIs was 15.8 ± 11.8 at initial visit and 1.5 ± 2.9 at 12-month follow-up (P < .001). No serious adverse events were reported.

Conclusions

Tildrakizumab has shown efficacy in clinical trials and this real-world cohort for the treatment of moderate to severe plaque psoriasis with a good safety profile. Future studies should be done to assess the efficacy of tildrakizumab compared with other IL-23 inhibitors.

Schlagwörter

Stichwörter der Autor:innen

Psoriasis Area and Severity Indexbiologics safetyinterleukin-23 inhibitorsplaque psoriasistildrakizumab

Autor:innen und Institutionen

  • The Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

ORCID-Profile: Nancy W Wei

Zitieren

APA

Wei, N. W., Chi, S., & Lebwohl, M. G. (2022). Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data. Journal of Psoriasis and Psoriatic Arthritis, 7(2), 55-59. https://doi.org/10.1177/24755303221077211

Vancouver

Wei NW, Chi S, Lebwohl MG. Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data. Journal of Psoriasis and Psoriatic Arthritis. 2022;7(2):55-59. doi:10.1177/24755303221077211

BibTeX
@article{Wei2022,
  author = {Wei, Nancy W and Chi, Sunny and Lebwohl, Mark G},
  title = {Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data},
  journal = {Journal of Psoriasis and Psoriatic Arthritis},
  year = {2022},
  volume = {7},
  number = {2},
  pages = {55--59},
  doi = {10.1177/24755303221077211}
}
Kostenlos starten →